Search - tctmd.com

Displaying 221 - 240 of 357

Sort: Relevancy | Date

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Industry News

Abbott Initiates Clinical Trial of Absorb™ in the United States

January 07, 2013

News Industry News

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

January 02, 2013

News Daily News

EES Outperform First-Generation DES in Treatment of CTOs

L.A. McKeown

December 27, 2012

News Daily News

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Caitlin E. Cox

December 26, 2012

News Daily News

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Caitlin E. Cox

December 26, 2012

Presentation

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

Presenter: K. W. Park

December 25, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

News Conference News TCT 2012

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

October 25, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

News Conference News TCT 2012

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

Presentation TCT 2012

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Presenter: James Hermiller Jr

October 23, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

News Conference News TCT 2012

New Results from SYNTAX, SPIRIT Trials Presented

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: Xience SBA Program Update

Presenter: David Rizik

October 22, 2012

News Conference News TCT 2012

COURAGE, FAME: Revascularization More Effective Than OMT

October 22, 2012

Advertisement

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Abbott Initiates Clinical Trial of Absorb™ in the United States

Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent System

EES Outperform First-Generation DES in Treatment of CTOs

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

ADAPT-DES: Poor Clopidogrel Response Not Predictive of 1-Year Mortality

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

ISAR-LEFT MAIN 2: Second-Generation DES Effective in Left Main CAD

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Several Trials Highlight DES Comparisons

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

New Results from SYNTAX, SPIRIT Trials Presented

Dedicated Bifurcation Stents: Xience SBA Program Update

COURAGE, FAME: Revascularization More Effective Than OMT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content